(0.33%) 5 116.76 points
(0.32%) 38 362 points
(0.38%) 15 988 points
(-0.99%) $83.02
(5.51%) $2.03
(0.34%) $2 355.20
(0.50%) $27.67
(4.14%) $960.25
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
@ $82.68
発行日: 14 2月 2024 @ 23:30
リターン: -17.11%
前回のシグナル: 2月 13 - 02:22
前回のシグナル:
リターン: -0.71 %
Live Chart Being Loaded With Signals
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial...
Stats | |
---|---|
本日の出来高 | 96 427.00 |
平均出来高 | 482 425 |
時価総額 | 4.39B |
EPS | $0 ( 2024-03-21 ) |
次の収益日 | ( $-0.670 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -31.58 |
ATR14 | $0.0750 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Shair Matthew | Sell | 14 156 | Class A Common Stock |
2024-04-22 | Shair Matthew | Sell | 8 694 | Class A Common Stock |
2024-04-22 | Shair Matthew | Sell | 14 650 | Class A Common Stock |
2024-04-15 | Shair Matthew | Sell | 25 600 | Class A Common Stock |
2024-04-15 | Shair Matthew | Sell | 11 900 | Class A Common Stock |
INSIDER POWER |
---|
-39.51 |
Last 100 transactions |
Buy: 784 474 | Sell: 1 684 248 |
ボリューム 相関
Nuvalent, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Nuvalent, Inc. 相関 - 通貨/商品
Nuvalent, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。